With negative FDA panel vote, AstraZeneca may look at narrow Lynparza nod in prostate cancer aliu Fri, 04/28/2023 – 13:31 More: With negative FDA panel vote, AstraZeneca may look at narrow Lynparza nod in prostate cancer Source: fierce
read moreOtsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify kdunleavy Fri, 04/28/2023 – 10:29 More: Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify Source: fierce
read moreThe first Humira biosim is doing Amgen more harm than good—for now aliu Fri, 04/28/2023 – 09:52 More: The first Humira biosim is doing Amgen more harm than good—for now Source: fierce
read moreGilead, looking to grow in oncology, posts big gains for its cell therapies and Trodelvy zbecker Fri, 04/28/2023 – 08:15 More: Gilead, looking to grow in oncology, posts big gains for its cell therapies and Trodelvy Source: fierce
read moreKite’s two CAR T-Cell therapies involve treating several different types of blood cancer More: NICE approves expanded use of Yescarta and Tecartus Source: News
read moreTherapy concerns the treatment of adults with axial spondyloarthritis and psoriatic arthritis More: Positive CHMP opinion for UCB’s bimekizumab Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals